X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (625) 625
Publication (112) 112
Patent (16) 16
Book Chapter (3) 3
Book / eBook (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (358) 358
hematology (225) 225
index medicus (177) 177
male (144) 144
female (140) 140
adult (131) 131
middle aged (130) 130
chronic myelogenous leukemia (121) 121
oncology (121) 121
aged (105) 105
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (103) 103
imatinib mesylate (95) 95
leukemia, myelogenous, chronic, bcr-abl positive - genetics (89) 89
chronic myeloid leukemia (87) 87
antineoplastic agents - therapeutic use (83) 83
hemic and lymphatic diseases (78) 78
adolescent (75) 75
treatment outcome (75) 75
benzamides (71) 71
imatinib (68) 68
pyrimidines - therapeutic use (67) 67
fusion proteins, bcr-abl - genetics (64) 64
bcr-abl (60) 60
chronic myeloid-leukemia (59) 59
leukemia (58) 58
piperazines - therapeutic use (58) 58
prognosis (57) 57
protein kinase inhibitors - therapeutic use (57) 57
mutation (53) 53
polymerase chain reaction (47) 47
aged, 80 and over (43) 43
dasatinib (41) 41
follow-up studies (41) 41
philadelphia chromosome (41) 41
cml (39) 39
animals (35) 35
follow-up (35) 35
tyrosine kinase inhibitors (35) 35
young adult (35) 35
abridged index medicus (33) 33
pyrimidines - administration & dosage (32) 32
therapy (32) 32
nilotinib (31) 31
care and treatment (30) 30
expression (30) 30
time factors (29) 29
base sequence (28) 28
cancer (28) 28
disease-free survival (28) 28
leukemia, myelogenous, chronic, bcr-abl positive - mortality (28) 28
leukemia, myeloid, chronic-phase - drug therapy (27) 27
reverse transcriptase polymerase chain reaction (27) 27
antineoplastic agents - administration & dosage (26) 26
hematology, oncology and palliative medicine (26) 26
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (26) 26
leukemia, myelogenous, chronic, bcr-abl positive - pathology (26) 26
philadelphia-chromosome (26) 26
minimal residual disease (25) 25
translocation, genetic (25) 25
chronic-phase (24) 24
drug resistance, neoplasm (24) 24
leukemia, myelogenous, chronic, bcr-abl positive - therapy (24) 24
mice (24) 24
survival rate (24) 24
antineoplastic agents - adverse effects (23) 23
piperazines - administration & dosage (23) 23
remission induction (23) 23
research (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
molecular sequence data (22) 22
pyrimidines - adverse effects (22) 22
acute lymphoblastic-leukemia (21) 21
blast crisis (21) 21
fusion proteins, bcr-abl - antagonists & inhibitors (21) 21
gene (21) 21
gene rearrangement (21) 21
genetic aspects (21) 21
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (21) 21
proto-oncogene proteins - genetics (21) 21
tyrosine kinase inhibitor (21) 21
antineoplastic agents (20) 20
disease progression (20) 20
dna-binding proteins - genetics (20) 20
interferon-alpha (20) 20
polymerase-chain-reaction (20) 20
protein-tyrosine kinases - antagonists & inhibitors (20) 20
tyrosine kinase (20) 20
karyotyping (19) 19
lymphoma (19) 19
molecular response (19) 19
mutations (19) 19
piperazines - adverse effects (19) 19
precursor cell lymphoblastic leukemia-lymphoma - genetics (19) 19
analysis (18) 18
child (18) 18
cml patients (18) 18
recurrence (18) 18
acute disease (17) 17
article (17) 17
chemistry (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 3, pp. 254 - 266
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5202 - 5207
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2016, Volume 11, Issue 9, pp. e0162866 - e0162866
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
The treatment of chronic myeloid leukemia (CML) achieved a great leap forward with the development of imatinib, a BCR-ABL kinase inhibitor. Alterations in the... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | PHASE CML-CP | MOLECULAR RESPONSES | UP SUSTAINED SURVIVAL | 800 MG | HARMONIZING CURRENT METHODOLOGY | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | PATIENTS PTS | BCR-ABL TRANSCRIPTS | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 35, pp. 6041 - 6051
Journal Article
American Journal of Hematology, ISSN 0361-8609, 08/2017, Volume 92, Issue 8, pp. 797 - 805
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 546 - 547
Journal Article
Nature, ISSN 0028-0836, 06/2008, Volume 453, Issue 7198, pp. 1072 - 1078
The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is... 
CHRONIC MYELOGENOUS LEUKEMIA | RETINOIC ACID | MULTIDISCIPLINARY SCIENCES | HEMATOPOIETIC STEM-CELLS | IMATINIB MESYLATE DISCONTINUATION | TUMOR-SUPPRESSOR | CANCER | ACUTE PROMYELOCYTIC LEUKEMIA | CHRONIC MYELOID-LEUKEMIA | ARSENIC TRIOXIDE | REMISSION | Recurrence | Tumor Suppressor Proteins - antagonists & inhibitors | Coculture Techniques | Humans | Transcription Factors - deficiency | Gene Expression Regulation, Neoplastic | Hematopoietic Stem Cells - pathology | Male | Arsenicals - therapeutic use | Neoplastic Stem Cells - metabolism | Tumor Suppressor Proteins - deficiency | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Nuclear Proteins - deficiency | Tumor Suppressor Proteins - genetics | Neoplastic Stem Cells - pathology | Adult | Female | Nuclear Proteins - genetics | Oxides - therapeutic use | Cell Line | Tumor Suppressor Proteins - metabolism | Arsenicals - pharmacology | Mice, Inbred C57BL | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Transcription Factors - metabolism | Oxides - pharmacology | Regeneration | Animals | Nuclear Proteins - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Promyelocytic Leukemia Protein | Care and treatment | Development and progression | Research | Chronic myeloid leukemia | Properties | Cancer cells | Physiological aspects | Tumor suppressor genes | Genetic aspects | Gene therapy | Health aspects | Oncogenes | Cancer | Proteins | Bone marrow | Stem cells
Journal Article